Mbx Biosciences, INC Form 4 insider transactions

MBX Biosciences, Inc. Director Tiba Aynechi was granted 16,000 stock options with an exercise price of $11.86, vesting based on continued service.

MBX Biosciences, Inc. Director James M. Cornelius has reported the acquisition of 16,000 stock options with an exercise price of $11.86, vesting on the earlier of one year or the next annual meeting.

MBX Biosciences, Inc. Director Steven Ryder was granted 16,000 stock options with an exercise price of $11.86, vesting on the earlier of one year or the next annual meeting.

Patrick J. Heron, a Director and 10% Owner of MBX Biosciences, Inc., acquired 16,000 stock options with an exercise price of $11.86, vesting on the earlier of one year or the next annual meeting.

MBX Biosciences Director Ora H. Pescovitz was granted 16,000 stock options with an exercise price of $11.86, vesting on the earlier of one year or the next annual meeting.

Director Ora H. Pescovitz of MBX Biosciences, Inc. reports purchasing 7,693 shares of common stock at an average price of $5.89 on April 8, 2025.

Director Steven L. Hoerter acquired stock options for 32,000 shares of MBX Biosciences, Inc. on April 7, 2025.

Carl Gordon, a director and 10% owner of MBX Biosciences, has increased his indirect holdings through open market purchases of common stock, executed via OrbiMed funds.

OrbiMed Advisors LLC, along with related entities, has increased its indirect beneficial ownership of MBX Biosciences, Inc. common stock through a series of purchases between February 14 and February 18, 2025.

Salomon Azoulay, Chief Medical Officer of MBX Biosciences, acquired stock options for 90,000 shares on February 3, 2025.

Richard Bartram, CFO of MBX Biosciences, acquired 95,000 stock options with an exercise price of $10.49 on February 3, 2025.

P. Kent Hawryluk, President & CEO of MBX Biosciences, recently acquired 50,000 shares of common stock and options to purchase 243,000 shares, demonstrating confidence in the company.

Edward T. Mathers, a director of MBX Biosciences, reports the conversion of Series A and B preferred stock into common stock and the purchase of additional common stock.

Following MBX Biosciences' IPO, Baskett Forest, a manager at NEA 17 GP, LLC, reported changes in beneficial ownership due to the conversion of preferred stock into common stock and the purchase of additional shares.

Ali Behbahani, a director and indirect owner of MBX Biosciences, reports changes in beneficial ownership following the company's initial public offering on September 16, 2024, including the conversion of preferred stock into common stock and the purchase of additional common stock.

Carmen Chang, a director and 10% owner of MBX Biosciences, reports the conversion of preferred stock to common stock and a purchase of 500,000 shares at $16 per share.

Anthony A. Florence Jr., a director and 10% owner of MBX Biosciences, reports transactions involving common stock and convertible preferred stock on September 16, 2024, following the company's IPO.

Mohamad Makhzoumi, a director of MBX Biosciences, reports the conversion of preferred stock and purchase of common stock following the company's IPO.

Paul Edward Walker, a director and 10% owner of MBX Biosciences, reports the conversion of Series A and B preferred stock into common stock and the purchase of additional common stock.

Rick Yang, a director of MBX Biosciences, reports the conversion of preferred stock into common stock and the acquisition of additional shares.

Scott D. Sandell, a director and indirect owner of more than 10% of MBX Biosciences, Inc., reports changes in beneficial ownership following the company's initial public offering.

OrbiMed Advisors LLC and related entities report changes in beneficial ownership of MBX Biosciences common stock and convertible preferred stock following the company's initial public offering on September 16, 2024.

New Enterprise Associates 17, L.P. reports changes in beneficial ownership of MBX Biosciences, Inc. common stock following the company's initial public offering on September 16, 2024, including conversions of preferred stock and open market purchases.

Frazier Life Sciences X, L.P. reports changes in beneficial ownership of MBX Biosciences stock following the company's initial public offering on September 16, 2024.

Director James M. Cornelius reported the conversion of Series A and Series B Convertible Preferred Stock into Common Stock immediately prior to MBX Biosciences' initial public offering on September 16, 2024.

Patrick J. Heron, a director and 10% owner of MBX Biosciences, reported the conversion of preferred stock and purchase of common stock following the company's initial public offering.

P. Kent Hawryluk, President & CEO of MBX Biosciences, reports the conversion of preferred stock to common stock in connection with the company's initial public offering.

Director Tiba Aynechi reports the conversion of Series B Convertible Preferred Stock into common stock and the purchase of additional common stock during MBX Biosciences' initial public offering.

Following MBX Biosciences' initial public offering, director Carl L. Gordon reports changes in beneficial ownership of common stock and convertible preferred stock.

Wellington Biomedical Innovation Master Investors (Cayman) II L.P. reports the conversion of Series B and Series C Preferred Stock to Common Stock in MBX Biosciences, Inc. upon the closing of the Issuer's initial public offering.